Can I read Zongertinib Na Primeira Linha CPNPC on EtoBox?

Zongertinib Na Primeira Linha CPNPC by Bruno Pozzi is a document available to read on EtoBox.

What is Zongertinib Na Primeira Linha CPNPC about?

The study evaluates the efficacy and safety of zongertinib, an oral tyrosine kinase inhibitor, as a first-line treatment for patients with advanced HER2-mutant non-small-cell lung cancer (NSCLC). In a cohort of 74 previously untreated patients, zongertinib demonstrated a 76% objective response rate with a median duration of response of 15.2 months, while treatment-related adverse events were predominantly low-grade. Additionally, in a subgroup with active brain metastases, 47% showed an intracranial objecti

Author

Bruno Pozzi

Language

EN